News

The median disease-free survival with GVAX vaccine plus low-dose cyclophosphamide; GVAX plus cyclophosphamide and nivolumab; and GVAX plus cyclophosphamide, nivolumab, and urelumab, was 13.90 months, 26.1 months, and 31.6 months, respectively.

Leana Cabrera Chien, MSN, RN, GCNS-BC, GNP-BC; and William Dale, MD, PD, discuss the new ASCO geriatric assessment guidelines and what they mean for nurses.

The FDA has approved a liver-directed therapy to treat metastatic uveal melanoma with hepatic metastases.

The FDA has granted accelerated approval to elranatamab-bcmm to treat adults with relapsed or refractory multiple myeloma who have already undergone 4 prior lines of treatment.

The FDA has issued a complete response letter to the new drug application for avasopasem manganese to manage oral mucositis in patients with locally advanced head and neck cancer undergoing radiation.

Two patients experienced 18% and 20% reductions in tumor size following treatment with camsirubicin.

Patients with relapsed/refractory primary mediastinal large B-cell lymphoma achieved antitumor responses with pembrolizumab.

The FDA has approved niraparib and abiraterone acetate to treat patients with deleterious or suspected deleterious BRCA-positive mCRPC, as detected by an FDA-approved test.

The FDA has approved the therascreen PDGFRA kit to identify patients with gastrointestinal stromal tumors who may benefit from treatment with avapritinib.

Oncology nurses make the case for nurse intervention with direct-to-consumer genomic testing.

Talquetamab has received accelerated approval for patients with relapsed or refractory multiple myeloma.

The FDA has granted regular approval to pralsetinib as a treatment for adults with metastatic RET fusion-positive non-small cell lung cancer.

There is room to improve drug adherence, patient education, and adverse event (AE) management for interstitial lung disease and cardiac AEs, according to Patricia Jakel, RN, MN, AOCN.

Relacorilant in combination with nab-paclitaxel did not meet the statistical significance threshold for progression-free survival vs nab-paclitaxel alone.

A single-arm study pilot study showed that patients' well-being scores significantly improved with the introduction of aromatherapy.

The resubmitted biologics license application for remestemcel-L has been issued a complete response letter.

I have been using the Epic Rover app on a hospital-provided iPhone for the last few months. It has helped me give medication faster and more efficiently.

Patients with recurrent or metastatic non–small cell lung cancer with EGFR exon 20 insertions achieved a confirmed objective response rate of 38.4% with zipalertinib.

Patients with colorectal cancer or non–small cell lung cancer who were treated in the outpatient setting and were not admitted 30 days prior to diagnosis experienced a statistically significant increase in delay of time to treatment initiation.

Leana Cabrera Chien, MSN, RN, GCNS-BC, GNP-BC, and William Dale, MD, PhD, discuss why geriatric assessments are important in providing individualized care.

Olaparib plus temozolomide was associated with a 27% overall response rate among 22 patients with pretreated uterine leiomyosarcoma.

Magnetic resonance-based imaging alone was 40% accurate in positively predicting pathologic complete response in patients with rectal adenocarcinoma undergoing total neoadjuvant therapy.

A triplet regimen of trifluridine, tipiracil, and bevacizumab has been approved as a treatment for patients with metastatic colorectal cancer.

The FDA has issued a complete response letter to the biologics license application for denileukin diftitox.

As evidence begins to mount supporting the efficacy of antibody-drug conjugates (ADCs), it is important that clinicians increase their knowledge of ADCs to improve the delivery of these agents.

Patients about to undergo Mohs microscopic surgery reported that they were more likely to request over-the-counter medications if they perceived their risk of opioid addiction to be high.

The FDA has approved dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient, as determined by an FDA-approved test, or microsatellite instability-high.

Patients with nonmetastatic clinically node positive bladder cancer who wish to avoid major surgery may achieve similar clinical outcomes with trimodal therapy.